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Abstract 
We report a novel, facile and asymmetric approach for the synthesis of the indole alkaloid harmicine via a highly 
diastereoselective N-acyliminium cyclization reaction as a key synthetic step, and verify the relative 
stereochemistry of the key synthetic intermediate in this approach through X-ray crystallography.  
 
 
Leishmaniasis, a disease spread by the bite of the sand fly, is found in tropical and sub-tropical regions, 
affecting some 12 million people in 88 countries. Symptoms of this disease vary from skin sores to 
fever, anaemia and damage to the spleen and liver. Common therapies have included the use of 
antimony-containing drugs, although less toxic treatments are currently in development.1 Screening of 
the leaf extract of the Malaysian plant Kopsia griffithii by Kam and Sim showed strong anti-leishmania 
activity that was traced back to the fraction containing the indolizidino[8,7-b]indole alkaloid, 
harmicine, 1.2 
 
 
Harmicine has previously been prepared in racemic form by Knolker and Agarwal,3 and asymmetric 
routes to (S)-ent-harmicine have been achieved by Ohsawa and co-workers, who were also able to 
establish that the absolute configuration of the naturally occurring compound was R.4 Our research 
group has had considerable success in the development of asymmetric routes to several important 
heterocyclic templates over recent years, based around the development of a highly diastereoselective 
N-acyliminium cyclization strategy.5 Our recent applications of this methodology in natural product 
synthesis has included targets from the erythrina group of alkaloids,5f,i and several indole alkaloids, 
including deplancheine.5a,d,e,g In this letter we report the successful application of our N-acyliminium 
strategy in a new asymmetric synthesis of (R)-harmicine, 1, the naturally occurring enantiomer. 
                                                
* Corresponding author. S.M.Allin@lboro.ac.uk 
N
Harmicine, 1
H
N
H
Our approach to harmicine began with the synthesis of imide 2, prepared from the β-amino alcohol 
derivative of (S)-tryptophan. Subjecting imide 2 to sodium borohydride reduction, as described in 
Scheme 1, resulted in direct and highly diastereoselective cyclization to give the indolizidino[8,7-
b]indole derivative 3 as a 9:1 mixture of diastereoisomers in 43% yield (Scheme 1). The major isomer 
was isolated by recrystallization from ethanol and its relative stereochemistry was confirmed by X-ray 
crystallographic analysis.6 (Scheme 1). Presumably, under the acidic reaction conditions, the electron-
rich indole moiety is able to cyclize onto the N-acyliminium intermediate that is generated in situ.  
 
Scheme 1. 
 
The stereochemical outcome of the reaction can be rationalized based on models previously proposed 
by our group for similar types of substrates.5k The high degree of stereocontrol arises from a preferred 
conformation, shown in Scheme 1, having minimal A(1,3) strain between the H-atom at the stereogenic 
centre of the tryptophanol moiety and the lactam carbonyl group in the transition state. 
 
To complete the synthesis of harmicine we were required to remove the hydroxymethyl auxiliary group 
from compound 3. Previous methods applied within our group to remove the hydroxymethyl 
“auxiliary” substituent from other heterocyclic templates has involved a rhodium-induced 
decarbonylation sequence.5f Due to the rather long reaction times generally needed for substrates in this 
decarbonylation protocol we have now applied a more facile approach that relies upon a 
decarboxylation strategy (Scheme 2), used successfully by our group in recent natural product 
syntheses.5a,d,e Compound 3 was oxidized to the carboxylic acid derivative 4 through the corresponding 
aldehyde; from 4 we generated the acyl selenide derivative and subsequently performed a tin-mediated 
deacylation to yield the core indolizidino[8,7-b]indole ring system 5. Deprotection of the indole 
nitrogen gave 6, from which reductive removal of the lactam carbonyl group completed the synthesis 
of the natural product, 1, (R)-(+)-harmicine, in 80% yield by LAH reduction in THF (Scheme 2). The 
optical rotation of our target compound, (R)-(+)-1, was determined to be +118.2 (c 1.6, CHCl3) and 
was comparable to that reported by Kam and Sim for the isolated natural product [+119; (c 0.086, 
CHCl3)].2 
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Scheme 2. (i) IBX, DMSO, RT, 24 h (72%); (ii) Et3N, (Boc)2O, DMAP, THF, RT, 4 h (73%); (iii) NaClO2, NaH2PO4, 
CH3CN, t-BuOH, cyclohexene, 0 °C to RT, 18 h (79%); (iv) (PhSe)2, PBu3, CH2Cl2, 0 °C to RT, 18 h (66%); (v) n-Bu3SnH, 
AIBN, toluene, Δ, 2 h (90%); (vi) TBAF, THF, Δ, 2 h then RT, 9 h (69%); (vii) LiAlH4, THF, Δ, 3 h (80%). 
 
In summary we have reported a new and highly stereoselective synthesis of the indolizidino[8,7-
b]indole alkaloid (R)-(+)-harmicine from a readily available, enantiomerically pure imide substrate. 7 
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